AIM ImmunoTech Inc reveals most recent advancements with its potential coronavirus treatment

AIM ImmunoTech Inc (NYSE American: AIM) CEO Thomas Equels tells Proactive the Florida-based biopharma group is working on setting up its pre-clinical structure to allow it to begin clinical trials to treat the coronavirus with its lead drug Ampligen.

What's more, Equels says the firm recently inked a deal to research vaping devices as a vehicle for Ampligen to treat the coronavirus.

treatment